# Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

> **NCT03436654** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 102 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** GnRH agonist/antagonist

## Key facts

- **NCT ID:** NCT03436654
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-21
- **Primary completion:** 2026-03-16
- **Final completion:** 2027-02-14
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436654, "Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03436654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*